Top executives at the three largest pharmacy benefit managers largely stuck to the script despite bipartisan skepticism and the growing frustration of the House Oversight and Accountability Committee with their testimony during a third hearing on industry reforms.
Key Takeaways
-
Leaders of the top three pharmacy benefit managers maintained they play a valuable role in lowering drug prices and denied putting costs before patient benefit during the House Oversight Committee's third PBM hearing.
The 23 July hearing was held with pressure building on PBMs from the Federal Trade Commission and state regulators. The...
